Dawn Witt

Dawn Witt, PhD, MPH

Program Director, Joseph F. Novogratz Family Heart Rhythm Center

Dawn Witt serves as Program Director of the Joseph F. Novogratz Family Heart Rhythm Center. Having been with the organization for over 13 years in varying positions from research assistant to senior scientist, Dawn has vast knowledge of the clinical research work at the Minneapolis Heart Institute Foundation.

Prior to MHIF, Dawn was at the University of Minnesota as a research assistant, where she also earned her PhD, MPH, and BA. Dawn’s extensive education in public health and nursing has led her to projects that combine healthcare research with community-driven health interventions to move toward creating accountable care communities. She brings research skills, cultural competency, and a creative outlook to healthcare projects focused on cardiovascular disease in populations often underrepresented in research.

Back to Heart Rhythm Team

Dawn Witt

Professional Interests:

  • Congenital heart disease
  • Women's heart health
  • Disparities in healthcare
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.